TNX-355 With Optimized Background Therapy (OBT) in Treatment-Experienced Subjects With HIV-1
Public ClinicalTrials.gov record NCT00089700. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Three-Arm Study of the Anti-CD4 Monoclonal Antibody TNX-355 With Optimized Background Therapy in Treatment-Experienced Subjects Infected With HIV-1
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a 48-week study to compare TNX-355 plus OBT to placebo plus OBT in HIV subjects. You must have a stable viral load of at least 10,000 copies/ml, been treated with highly active antiretroviral therapy (HAART) for at least 6 months, be triple class experienced, and presently failing or have failed a HAART regimen. Subjects will receive infusions every week for 8 weeks, then every two weeks.
Study identification
- NCT ID
- NCT00089700
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 80 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2004 (Type not available)
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Jun 24, 2005
Started 2004
United States locations
- U.S. sites
- 13
- U.S. states
- 8
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Body Positive | Phoenix | Arizona | 85006 | — |
| Altamed Corporation | Los Angeles | California | 90022 | — |
| Tower ID Medical Associates | Los Angeles | California | 90048 | — |
| Dupont Circle Physicians Group | Washington D.C. | District of Columbia | 20009 | — |
| IDC Research Initiative | Altamonte Springs | Florida | 32701 | — |
| Bach and Godofsky | Bradenton | Florida | 34205 | — |
| University of Miami | Miami | Florida | 33136 | — |
| Comprehensive Research Institute | Tampa | Florida | 33607 | — |
| Brobson Lutz, MD, LLC | New Orleans | Louisiana | 70115 | — |
| Chase-Brexton Health Services, Inc. | Baltimore | Maryland | 21201 | — |
| Johns Hopkins University School of Medicine | Baltimore | Maryland | 21205 | — |
| University of Cincinnati Medical Center | Cincinnati | Ohio | 45267 | — |
| Tanox, Inc. | Houston | Texas | 77025 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00089700, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 24, 2005 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00089700 live on ClinicalTrials.gov.